Arecor Therapeutics PLC Collaboration With Top 10 Global Pharma (5587J)
August 17 2023 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 5587J
Arecor Therapeutics PLC
17 August 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR TO COLLABORATE WITH TOP 10 GLOBAL PHARMACEUTICAL
COMPANY
Arecor expands its global partnerships through collaboration to
develop an enhanced antibody formulation
Cambridge, UK, 17 August 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that it has signed an
agreement with a top 10 pharmaceutical company to develop an
enhanced antibody formulation for one of its investigational
drugs.
Under the terms of this agreement, Arecor will use its
proprietary formulation technology platform, Arestat(TM), to
develop a novel, stable formulation of a liquid, high concentration
antibody. The collaborator will fund the development work,
generating new revenue for Arecor. This agreement adds to Arecor's
growing portfolio of partnerships.
Sarah Howell, Chief Executive Officer of Arecor, said: "This
collaborator is a leader in the development of novel medicines.
Arecor has a proven track record of leveraging its Arestat
technology to help deliver these complex therapeutics. We work
closely with our partners to develop more effective treatments
where superior properties bring even greater benefit to patients
and we look forward to working with the world-renowned R&D
team."
This announcement contains inside information for the purposes
of the retained UK version of the EU Market Abuse Regulation (EU)
596/2014 ("UK MAR").
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver therapeutic products. The Arestat (TM) platform is
supported by an extensive patent portfolio .
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAKPKFSADEFA
(END) Dow Jones Newswires
August 17, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024